Get started
Author

Hélène Lasolle

Observed names: H Lasolle, H. Lasolle, Helene Lasolle, Hélene Lasolle, Lasolle H, Lasolle Helene, Lasolle Hélène, Lasolle, Hélène
Institutions: Lyon 1 Université, Centre National de la Recherche Scientifique, Inserm, Hospices Civils de Lyon, Centre de Recherche en Cancérologie de Lyon, Physiopathologie, diagnostic et traitements des maladies musculo-squelettiques, Hôpital Louis Pradel
Observed institutions: Lyon 1 Université, Centre National de la Recherche Scientifique, Université Libre de Bruxelles, University of Padua, Inserm, Lund University, Université de Lyon, Hospices Civils de Lyon, Hôpital Pierre Wertheimer, Health Services and Performance Research Laboratory, Centre de Recherche en Cancérologie de Lyon, Physiopathologie, diagnostic et traitements des maladies musculo-squelettiques, Laboratoire de Biométrie et Biologie Evolutive, Hôpital Louis Pradel, Research on healthcare performance, Centre pour l'innovation en cancérologie de Lyon
ORCID: 0000-0002-5027-7660
Observed ORCID: 0000-0002-5027-7660
OpenAlex ID: A5080825844
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
2018 · Ann McCormack, Olaf M Dekkers, et al. · European Journal of Endocrinology · 287
PDF
Aggressive pituitary tumours and pituitary carcinomas
2021 · Gérald Raverot, Mirela Diana Ilie, et al. · Nature Reviews Endocrinology · 194
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas
2017 · Hélène Lasolle, Christine Cortet, et al. · European Journal of Endocrinology · 140
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients
2022 · Pia Burman, Pia Burman, et al. · European Journal of Endocrinology · 110
PDF
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
2023 · Massimo Terzolo, Martin Fassnacht, et al. · The Lancet Diabetes & Endocrinology · 85
PDF
Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France
2022 · Alexandre Dormoy, Magalie Haissaguerre, et al. · The Journal of Clinical Endocrinology & Metabolism · 72
PDF
Transplantable human thyroid organoids generated from embryonic stem cells to rescue hypothyroidism
2022 · Mírian Romitti, Adrien Tourneur, et al. · Nature Communications · 64
PDF
PFMG2025–integrating genomic medicine into the national healthcare system in France
2025 · Caroline Abadie, Aldja Abderrahmane, et al. · The Lancet Regional Health - Europe · 57
PDF
Emerging and Novel Treatments for Pituitary Tumors
2019 · Mirela Diana Ilie, Hélène Lasolle, et al. · Journal of Clinical Medicine · 56
PDF
Pasireotide: A potential therapeutic alternative for resistant prolactinoma
2018 · Hélène Lasolle, Alexandre Vasiljevic, et al. · Annales d Endocrinologie · 55
PDF
Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis
2020 · Hélène Lasolle, Mad-Hélénie Elsensohn, et al. · Acta Neuropathologica Communications · 50
PDF
SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors
2020 · Solène Castellnou, Alexandre Vasiljevic, et al. · Endocrine Connections · 48
PDF
Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm
2022 · Francesco Calvanese, Timothée Jacquesson, et al. · Frontiers in Endocrinology · 47
PDF
Age- and Sex-Specific TSH Upper-Limit Reference Intervals in the General French Population: There Is a Need to Adjust Our Actual Practices
2020 · Véronique Raverot, Maxime Bonjour, et al. · Journal of Clinical Medicine · 44
PDF
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
2023 · Hélène Lasolle, Andrea Schiavo, et al. · Oncogene · 41
PDF
Aggressive prolactinomas: how to manage?
2019 · Hélène Lasolle, Mirela Diana Ilie, et al. · Pituitary · 39
Aggressive corticotroph tumors and carcinomas
2022 · Hélène Lasolle, Alexandre Vasiljevic, et al. · Journal of Neuroendocrinology · 38
Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours
2023 · Julia Simon, Luis Gustavo Perez-Rivas, et al. · European Journal of Endocrinology · 36
Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
2019 · Hélène Lasolle, Amandine Ferriere, et al. · Endocrine Connections · 32
PDF
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer
2018 · Francoise Borson-Chazot, Emmanuelle Dantony, et al. · Thyroid · 32
Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors
2019 · Gerald Raverot, Alexandre Vasiljevic, et al. · European Journal of Endocrinology · 31
Pneumocystis pneumonia in patients with Cushing's syndrome: A French multicenter retrospective study
2022 · Alexandre Lugat, Hélène Lasolle, et al. · Annales d Endocrinologie · 24
Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
2021 · Massimo Terzolo, Martin Fassnacht, et al. · Journal of the Endocrine Society · 24
PDF
A Preclinical Rat Model of Heart Failure With Preserved Ejection Fraction With Multiple Comorbidities
2022 · Géraldine Hubesch, Aliénor Hanthazi, et al. · Frontiers in Cardiovascular Medicine · 15
PDF
Postoperative remission of non-invasive lactotroph pituitary tumor: A single-center experience
2021 · Hélène Lasolle, Marie Teulade, et al. · Annales d Endocrinologie · 14
PDF
Works count: 136
Citation count: 1,807
H-index: 23
I10-index: 29
Year
Topic
Type